Shares of Minerva Neurosciences, Inc. (NASDAQ:NERV – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.97 and traded as low as $2.59. Minerva Neurosciences shares last traded at $2.61, with a volume of 3,790 shares.
Analyst Ratings Changes
Several equities analysts have recently commented on NERV shares. StockNews.com started coverage on Minerva Neurosciences in a research report on Saturday. They issued a “sell” rating on the stock. HC Wainwright dropped their price target on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.
Check Out Our Latest Stock Report on Minerva Neurosciences
Minerva Neurosciences Stock Up 0.8 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Analysts forecast that Minerva Neurosciences, Inc. will post -2.26 EPS for the current year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- Bank Stocks – Best Bank Stocks to Invest In
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Why Are These Companies Considered Blue Chips?
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- What is a Special Dividend?
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.